Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idiotype-pulsed dendritic cells
- Development stage
- Phase 1
- Lead developer
- Stanford University School of Medicine
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
Idiotype-pulsed dendritic cells are a form of personalized cellular immunotherapy in which autologous dendritic cells are loaded (pulsed) with the tumor-specific idiotype protein (clonal immunoglobulin unique to the patient's B-cell malignancy) and administered to the patient to elicit an anti-tumor immune response. The approach aims to induce both T-cell and humoral immune responses specifically against malignant B cells, making use of dendritic cells’ exceptional capacity for antigen presentation. Keyhole limpet hemocyanin (KLH) may be used as a carrier to augment immunogenicity. This investigational modality has been evaluated mainly in B-cell lymphoma and multiple myeloma, and studies indicate it is safe and immunogenic, with some evidence for tumor regression and prolonged progression-free survival, though clinical efficacy remains under investigation[1][2][3][6][8].
- Other names
- idiotype-pulsed DCsidiotype-pulsed antigen presenting cellsidiotype-loaded dendritic cells
02
Targets
γδ TCR (T-cell receptor)Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on idiotype-pulsed dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idiotype-pulsed dendritic cells.